“What we’ve shown is [EV/pembrolizumab] outperforming chemotherapy in all subgroups," says Thomas B. Powles, MBBS, MRCP, MD. Treatment of locally advanced or metastatic urothelial carcinoma with ...

“We already have very effective ARPIs available around the world, and this will add to those therapeutic options to try to tailor patients based on their needs [and] their particular profiles,” says ...

According to the authors, data from the CONTACT-02 trial show that cabozantinib plus atezolizumab may benefit selected patients with mCRPC. Data from the final overall survival (OS) analysis from the ...

Patients with at least 1 NE-positive marker were shown to have a worsened rPFS and OS. Certain phenotypic and genomic biomarkers were found to be prognostic for radiographic progression-free survival ...

Median OS was 35.0 months in the enzalutamide-alone arm vs 42.3 months in the combination arm. The combination of enzalutamide (Xtandi) plus radium-223 (Ra223, Xofigo) for the treatment of metastatic ...

In the experimental arm, 41% of patients had an undetectable PSA level at week 48 vs 16% in the control arm (OR=3.88; 95% CI, 1.61-9.38, P = .002). The combination of 177Lu-PSMA-617 (lutetium Lu 177 ...

On Cox regression analysis, glycoproteins were predictive of PFS response to nivolumab plus cabozantinib vs sunitinib (P < .01). Serum glycoproteins involved in complement cascade and lipid metabolism ...

“I think that these data in this approximately 700 patient trial consolidates and makes a strong case for the role of pembrolizumab in the adjuvant setting,” says Guru P. Sonpavde, MD. In this video, ...

“NKT2152 demonstrated robust anti-tumor activity in a heavily pretreated, high-risk advanced clear cell renal cell carcinoma population," said Eric Jonasch, MD. The investigational oral HIF-2α ...

New findings from the open-label SPLASH trial show patients with mCRPC achieved improved progression-free survival as well as response rates and antigen-specific reductions. Prostate-specific membrane ...

“Today, we're presenting the results of this analysis, and we show that patients who have a high Decipher score derive significant benefit from docetaxel,” says Gerhardt Attard, MD, PhD, FRCP. In this ...

Investigators observed promising clinical effect with the EGFR / HER3 bispecific antibody-drug conjugate. Epidermal growth factor receptor (EGFR) / epidermal growth factor 3 (HER3) bispecific antibody ...